Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older

Herpes Zoster Clinical Trial

Official title:

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy, Safety and Immunogenicity of Recombinant Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06447779
• Other study ID #: MKKCT-100-003
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 2024
• Est. completion date: September 2027

Study information

• Verified date: May 2024
• Source: MAXVAX Biotechnology Limited Liability Company
• Contact: Wang Yanxia, Master
• Phone: +86 13613816598
• Email: wangyanxia99[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.

Description:

A total of 25000 adults aged 40 years and older will be enrolled, stratified into 40-49, 50-59, 60-69 and ≥70 years of age. All subjects will randomly receive investigational vaccine or placebo at a ratio of 1:1. Efficacy and safety will be assessed in all subjects, while immunogenicity will be assessed in a subset of 1250 subjests in a selected trial site.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 25000
• Est. completion date: September 2027
• Est. primary completion date: September 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. A male or famale permanent resident aged 40 years and older at enrollment, with valid identity;

2. Subjects voluntarily agree to participate in the study and signed an informed consent;

3. Be able to understand clinical trials, participate in all scheduled visits and comply with the protocol requirements(e.g. completion of the diary cards/questionnaires, return for follow-up visits, have regular contact to allow evaluation during the study);

4. Women of childbearing potential plan to aviod pregnancy and are willing to use effcetive contraception(e.g. oral contraceptive pills, injectable progestogen, percutaneous contraceptive patches, implants of levonorgestrel, intrauterine device, female and male sterilization or abstinence) within 12 months after the last vaccination, and the uses of the rhythm method alone, withdrawal alone, and emergency contraception, are not acceptable.

Exclusion Criteria:

1. Axillary temperature>37.0?;

2. Current or history of herpes zoster;

3. Previous vaccination against varicella or herpes zoster (either registered product or participation in a previous vaccine study);

4. Pregnant (urine pregnancy test was positive) or lactating female;

5. Receipt of live vaccine within 28 days, or any other vaccine within 14 days prior to vaccination;

6. Receipt of immunoglobulin or intravenous immunoglobulin during 3 months before vaccination to 1 month post the last vaccination;

7. Acute diseases or acute exacerbation of chronic disease within 3 days before vaccination;

8. Receipt of antipyretic, analgesic and allergy drugs within 3 days before vaccination, except enteric-coated aspirin for cardiovascular diseases prevention;

9. A known allergy to any components of the study vaccine, or history of severe allergy (e.g. Anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, Arthus reaction, severe urticaria) to any previous vaccination;

10. Allergy to aminoglycoside antibiotics;

11. History of convulsions, epilepsy, encephalopathy (e.g. congenital brain dysplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection disease, nerve tissue damage caused by chemical drug poisoning), mental illness and family history, and other serious neurological diseases;

12. Asplenia or functional asplenia, or splenectomy caused by any condition;

13. Primary or secondary impairment of immune function, diagnosed congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease or other autoimmune diseases;

14. Receipt of immunosuppressive therapy (e.g. long-term use of systemic glucocorticoid =14 days, dose =2mg/kg/day or =20mg/day prednisone or equivalent dose) during 6 months before vaccination to 1 minth post the last vaccination, but inhaled, nasal spray, intra-articular, eyedrops, ointment and other topical steroids are acceptable;

15. Receipt of long-acting immune-modifying drugs (e.g. Infliximab) within 6 months before vaccination or during the study period;

16. Severe chronic disease, including but not limited to, severe cardiovascular disease(e.g. Pulmonary heart disease, Pulmonary Edema), severe liver or kidney disease, or diabetes with complication;

17. History of thrombocytopenia or other coagulation disorders, which may cause intramuscular injection contraindications;

18. Abnormal and uncontrlled blood pressure during physical examination before vaccination (for subjects aged 40-59: systolic pressure = 140 mmHg and/or diastolic pressure = 90 mmHg; for subjects aged =60, systolic pressure = 150 mmHg and/or diastolic pressure = 100 mmHg);

19. History of drug abuse (narcotic drugs, psychotropic drugs);

20. Current skin infections, in the opinion of the investigator, might interfere with the efficacy evaluation;

21. Current or history of malignant tumors, except papillary thyroid carcinoma;

22. Receipt of investigational products (drugs or vaccines) within 6 months before vaccination;

23. Planned participation in another clinical study during the study period;

24. Any condition that, in the opinion the investigator, may affect the safety of the subject or the evaluation of the study results.

Related Conditions & MeSH terms

• Herpes Zoster

Intervention

Biological:
• Recombinant Zoster Vaccine (CHO Cell)
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection
• NaCl solution Placebo
0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection

Locations

Country	Name	City	State
China	Yunnan Center For Disease Control and Prevention	Kunming	Yunnan
China	Hebei Provincial Center for Disease Control and Prevention	Shijiazhuang	Hebei
China	Hubei Provincial Center for Disease Control and Prevention	Wuhan	Hubei
China	Henan Center for Diseases Control and Prevention	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
MAXVAX Biotechnology Limited Liability Company

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of confirmed Herpes Zoster(HZ) Cases per person years in subjects aged 40 years and older	A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the Endpoint Adjudication Committee (EAC), consisting of physicians with HZ expertise.	30 days after the last vaccination
Secondary	Incidence of confirmed Herpes Zoster(HZ) Cases per person years in different age group.	All subjects will be stratified into 40-49 years, 50-59 years, 60-69 years and =70 years of age.	30 days after the last vaccination
Secondary	Incidence of any and severe Postherpetic Neuralgia (PHN) cases per person years in subjects aged 40 years and older, 40-49years , 50-59 years , 60-69 years and =70 years , with confirmed HZ.	PHN of any severity was defined as 0 and greater on the Zoster Brief Pain Inventory(ZBPI) questionnaire, while severe PHN rated as 3 and greater on the ZBPI questionnaire.	30 days after the last vaccination
Secondary	Geometric Mean Concentration(GMC) of anti-gE antibody and anti-VZV antibody in immunogenicity subset	Measured by ELISA	At 1, 12, 24 and 36 months after the last vaccination
Secondary	Seropositivity rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset	The seropositivity rate is defined as the percentage of subjects whose antibody concentration is greater than or equal to the cut-off value.	At 1, 12, 24 and 36 months after the last vaccination
Secondary	Seroresponse rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset	The seroresponse rate is defined as the percentage of subjects who have at least a: 4-fold increase in the antibody concentration as compared to the pre vaccination antibody concentration, for subjects who are seropositive at baseline, OR, 4-fold increase in the antibody concentration as compared to the antibody concentration cut-off value for seropositivity, for subjects who are seronegative at baseline.	30 days after the last vaccination
Secondary	Geometric Mean Fold Rise (GMFR) of anti-gE antibody and anti-VZV antibody in immunogenicity subset	The antibody concentration at evaluted time points compared with that at baseline.	At 1, 12, 24 and 36 months after the last vaccination
Secondary	Four-fold increase rate of anti-gE antibody and anti-VZV antibody in immunogenicity subset	The antibody concentration 30 days after the last vaccination compared with that at baseline.	30 days after the last vaccination
Secondary	Cell-Mediated Immunity (CMI) response	CMI response is defined as the frequency of CD4+ T cells producing at least 2 activation markers (IFN-?, IL-2, TNF-a and/or CD40L) upon in vitro stimulation by gE peptide pools.	30 days after the last vaccination
Secondary	Vaccine Response Rate (VRR)	VRR is defined as the percentage of subjects with at least a 2-fold increase as compared to the Cut-off, for subjects with pre-vaccination T-cell frequencies	30 days after the last vaccination
Secondary	Number of Participants With solicited local symptoms	Assessed solicited local symptoms were pain, Induration, swelling, redness, pruritus, rash, and cellulitis.	Within 7 days after each vaccination
Secondary	Number of Participants With solicited general symptoms.	Assessed solicited general symptoms were fever [defined as axillary equal to or above 37.3 degrees Celsius (°C)], diarrhoea, anorexia, vomiting, nausea, abdominal pain, myalgia, arthralgia, headache, syncope, new convulsions, cough, pruritus (non-vaccination site), skin and mucous membrane abnormalities, acute allergic reactions, fatigue, pain (non-vaccination site), chills.	Within 7 days after each dose
Secondary	Number of Participants With unsolicited adverse events	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.	During 30 days after each vaccination
Secondary	Number of Participants With Serious Adverse Events	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.	From the day of first vaccination up to 12 months after last vaccination
Secondary	Number of Participants With potential Immune Mediated Disorders	pIMDs are a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.	From the day of first vaccination up to 12 months after last vaccination